Nasdaq grants VYNE Therapeutics (VYNE) more time to fix sub-$1 share price

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

VYNE Therapeutics Inc. received an extension from Nasdaq to regain compliance with its minimum bid price listing rule. The company had previously failed to lift its common stock closing bid price back to at least $1.00 for 30 consecutive business days by March 10, 2026.

Nasdaq granted VYNE an additional 180 days, until September 7, 2026, to meet the $1.00 minimum bid price requirement. VYNE’s stock will continue trading on the Nasdaq Capital Market under the symbol “VYNE” during this period, and the company is considering options such as a potential reverse stock split to restore compliance.

Positive

None.

Negative

Continued Nasdaq bid-price noncompliance and delisting risk: VYNE failed to regain the required $1.00 minimum bid price by March 10, 2026. While Nasdaq granted an extension to September 7, 2026, the company faces potential delisting from the Nasdaq Capital Market if it cannot demonstrate compliance by then.

Insights

Nasdaq granted VYNE more time to fix its sub‑$1 share price but delisting remains a clear risk.

VYNE Therapeutics remains out of compliance with Nasdaq’s minimum bid price rule because its common stock closed below $1.00 for 30 straight business days. The company missed the initial March 10, 2026 deadline to cure this deficiency.

Nasdaq has now provided a second 180‑day compliance period, running through September 7, 2026. The stock will stay listed on the Nasdaq Capital Market during this window, as VYNE still meets other initial listing standards, including market value of publicly held shares.

If the closing bid price reaches at least $1.00 for 10 consecutive business days before September 7, 2026, Nasdaq will deem VYNE back in compliance. Otherwise, Nasdaq plans to move toward delisting, though VYNE could appeal to a Hearings Panel. Management explicitly mentions a possible reverse stock split as one option to regain compliance.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

Why did VYNE (VYNE) receive a Nasdaq noncompliance notice for its stock?

VYNE fell out of compliance because its common stock closing bid price stayed below $1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires at least a $1.00 minimum bid price to maintain listing on the Nasdaq Capital Market.

How long does VYNE (VYNE) have to regain Nasdaq minimum bid price compliance?

VYNE now has until September 7, 2026 to regain compliance with Nasdaq’s $1.00 minimum bid price rule. This follows an initial 180‑day period that ended March 10, 2026, during which the company did not cure the deficiency.

What must happen for VYNE (VYNE) to be back in compliance with Nasdaq rules?

VYNE will be back in compliance if its common stock closing bid price is at or above $1.00 per share for at least 10 consecutive business days before September 7, 2026. Nasdaq would then formally notify the company that the minimum bid price requirement is satisfied.

What happens if VYNE (VYNE) does not meet Nasdaq’s bid price requirement by September 7, 2026?

If VYNE cannot show compliance with the $1.00 minimum bid price requirement by September 7, 2026, Nasdaq plans to notify the company that its common stock will be delisted from the Nasdaq Capital Market. VYNE could then appeal this determination to a Nasdaq Hearings Panel.

Is VYNE (VYNE) still trading on the Nasdaq Capital Market after the extension?

Yes. The extension notice has no immediate effect on the listing or trading of VYNE’s common stock. Shares continue to trade on the Nasdaq Capital Market under the symbol “VYNE” while the company works to regain minimum bid price compliance.

What actions might VYNE (VYNE) take to regain Nasdaq bid price compliance?

VYNE intends to monitor the closing bid price of its common stock and may consider available options, including a reverse stock split of its outstanding securities during the second compliance period, if appropriate, to restore compliance with Nasdaq’s minimum bid price requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/11/2026 - 04:57 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2026

VYNE Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38356

45-3757789

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

P.O. Box 125
Stewartsville, NJ 08886

(Address of principal executive offices, including Zip Code)

(800) 775-7936

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value

VYNE

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. (the “Company”) on September 12, 2025, the Company received a notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The Company initially had 180 calendar days, or until March 10, 2026, to regain compliance with the minimum bid price requirement. The Company was unable to regain compliance with the minimum bid price requirement by March 10, 2026.

On March 11, 2026, the Company received a letter (the “Extension Notice”) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until September 7, 2026, to regain compliance with the minimum bid price requirement. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Extension Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “VYNE.”

If at any time before September 7, 2026, the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it is in compliance with the minimum bid price requirement. However, if compliance with the minimum bid price requirement cannot be demonstrated by September 7, 2026, Nasdaq will notify the Company that its common stock will be delisted from The Nasdaq Capital Market, at which time, the Company may appeal Nasdaq’s determination to a Hearings Panel.

The Company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities during the second compliance period, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VYNE THERAPEUTICS INC.

Date: March 11, 2026	By:	/s/ Mutya Harsch
		Mutya Harsch
		Chief Legal Officer and General Counsel

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents